

REGISTERED COMPANY NUMBER: 06268494 (England and Wales)
REGISTERED CHARITY NUMBER: 1120756

REPORT OF THE TRUSTEES AND
UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2024
FOR
PULMONARY HYPERTENSION ASSOCIATION UK

Wyatt Morris Golland Ltd
Park House
200 Drake Street
Rochdale
Lancashire
OL16 1PJ

PULMONARY HYPERTENSION ASSOCIATION UK

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024**

	Page
Reference and Administrative Details	1
Report of the Trustees	2 to 10
Independent Examiner's Report	11
Statement of Financial Activities	12
Balance Sheet	13
Cash Flow Statement	14
Notes to the Cash Flow Statement	15
Notes to the Financial Statements	16 to 25

PULMONARY HYPERTENSION ASSOCIATION UK

**REFERENCE AND ADMINISTRATIVE DETAILS
FOR THE YEAR ENDED 30 APRIL 2024**

TRUSTEES

I J Armstrong
K Yeowart
S Townsley
T Yeldham
J Royle (appointed 7.7.23)

The trustees are collectively referred to as both the board of trustees and the Management Committee. They are also directors for the purposes of the Companies Act.

REGISTERED OFFICE

Unit 1, Newton Business Centre
Newton Chambers Road, Thorncliffe Park
Chapeltown
Sheffield
S35 2PH

REGISTERED COMPANY NUMBER 06268494 (England and Wales)

REGISTERED CHARITY NUMBER 1120756

INDEPENDENT EXAMINER

Wyatt Morris Golland Ltd
Park House
200 Drake Street
Rochdale
Lancashire
OL16 1PJ

FINANCE OFFICER

S Clayton

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 30 APRIL 2024**

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 30 April 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

The main object of the charity is to raise awareness of pulmonary hypertension. Raising awareness is difficult to measure quantitatively making it difficult to accurately assess the performance of the charity. Detailed below is a synopsis of the year's activities and achievements which aim to demonstrate qualitatively how the charity goes about meeting its objectives of raising awareness and providing financial assistance in cases of need.

Awareness is raised through the provision of information and educational resources for sufferers of the said condition, their families, carers and members of the medical profession.

In addition the charity also provides relief of need of sufferers of the said condition, their families and carers through the provision of financial assistance towards, but not exclusively, respite care, travel grants and equipment grants at the discretion of the Executive committee, as and when resources allow.

Public benefit

We review our aims, objectives and activities each year. This review looks at what we achieved and the outcomes of our work in the previous 12 months. The review looks at the success of each key activity and the benefits they have brought to those groups of people we are set up to help. The review also helps us to ensure our aim, objectives and activities remained focused on our stated purposes. We have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aims and objectives and in planning our future activities. In particular, the management committee consider how planned activities will contribute to the aims and objectives they have set.

Grantmaking

Requests of £500 or under require an administrator signature, and from £500 to £2,000 need to be agreed by the administrator and a trustee. Grants are only paid to an individual and not an institution.

A monthly grant limited to £5,000 is set. If this is to be surpassed it must be agreed by two executive trustees.

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 30 APRIL 2024**

ACHIEVEMENT AND PERFORMANCE

PHA UK: Our Year - An overview of our work during 2023/24

MEMBER SERVICES, SUPPORT, AND RESOURCES

Most of our staffing resources and financial outlays this year have been invested into supporting people living with PH.

We have produced information resources including a printed publication about PH and menopause; recognising that this is an important subject, given the demographics of those affected by PH. This resource has been extremely well-received, and it was supported by two staff members attending a conference around nutrition and menopause.

One of our flagship publications, PH & Medication, was reviewed, updated and re-printed, and ongoing reviews and updates of PH & You and PH & Palliative Care were carried out too.

This work was all carried out in line with the Patient Information Forum (PIF) standards and our commitment to producing quality information was once again recognised with the re-certification of the PIF quality mark - which we received for the third year running.

In September 2023, we launched a new publication to help those newly diagnosed with PH learn from people with lived experience of the condition. Words of Wisdom includes advice from across the PH community and it is now a key part of new PHA UK member packs. To help as many people as possible to benefit from its content, we also commissioned the production of an accompanying animation, which is shared regularly across our social media platforms.

In October 2023, we held an extremely valuable patient gathering in Sheffield - the first of its kind since the COVID-19 pandemic. The Together Sheffield event was held at a hotel and attended by patients and their loved ones from across the surrounding areas. Collaborating with experts from the Sheffield Pulmonary Vascular Disease Unit, we hosted a series of educational talks and provided valuable opportunities for delegates to make connections and form friendships.

Feedback from those who attended included:

"Thank you for putting on such a lovely day. Very informative and was nice to see other people living with the condition."

"I loved it, everything was so easy to understand and I took away quite a lot from the day."

"It was a fantastic day, well organised fun informative and fantastic to see lots of other people in the same boat."

The success of this inaugural event has led to the planning of further regional gatherings.

In January 2024, we collaborated with a PHA UK member to launch a new book to help children with PH understand more about their condition. Exploring PH with KiKi the Koala was written and designed by Maryam Hussain, who was inspired by her little sister's experiences with the disease. We covered the print and production costs to allow as many families as possible to benefit from this unique publication. Its popularity has already led to translation requests from other countries.

In early 2024, we collaborated with the Sheffield Pulmonary Vascular Disease Unit to produce information packs for those newly diagnosed with PH. They were designed for all new patients to provide a comprehensive introduction to the specialist service in Sheffield, allay anxieties, and signpost to helpful PHA UK resources.

To coincide with the production of these packs, we developed a new area of our website to bring together the most helpful resources for those newly diagnosed with PH. This online platform is accessed by people from all over the UK.

In February 2024, we collaborated with the UK-wide CHAMPION group (Congenital Heart disease And pulMonary arterial hyPertension: Improving Outcomes through education and research Networks) to begin the development of a suite of resources for people living with both congenital heart disease and PH.

To understand the information needs of this population, we conducted a comprehensive survey for both patients and caregivers (which led to a focus group later in the year).

Three issues of emPHAsis, our member magazine, were produced and published this year. The autumn 2023 edition was accompanied by a survey to help us understand what people valued most, or would like to see more of, in the magazine, and the findings have helped us refine our content to be of most use to our community.

Feedback provided via the survey included:

"Each time Emphasis arrives I realise I am not alone...The feeling of isolation disappears."

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 30 APRIL 2024**

"I expect [this magazine] is a lifeline for many."

"It is such a good read and helps me enormously."

"When I read about people who have this condition - like me but of all ages - it gives me hope, courage, and determination."

Alongside the production of emPHAsis, we also curated and distributed 12 monthly e-newsletters, to keep members up-to-date and foster a continued feeling of connection.

From February 2024 onwards, we played a vital role in helping patients understand a fast-moving crisis situation regarding the shortage of an intravenous drug therapy. Supply chain interruption meant stocks of Flolan (epoprostenol) were low and at risk of becoming unavailable, and we produced timely and accurate information resources to help the PH community understand the situation and allay anxieties. This involved weekly meetings with the drug manufacturers and supply chain, and the PHA UK played an important role in holding the manufacturers to account for the impact on the community.

We have continued to provide regular updates on the emergence of the new PAH drug therapy sotatercept, with communications including the production of videos with researchers and clinicians to bring people trusted and high-quality information.

Our Listening Line supportive call service, and dedicated email support service, have continued to help people in the ways that suit them best - with daily interactions between service users and staff.

Our nutrition email advice service has also continued to provide bespoke support, and alongside this, we have continued to create advice pieces and video resources for our dedicated web area. The collaboration with dietician Chermaine Kwant has also been central to the development of these resources.

As part of our focus on supporting people's general wellbeing, we have established a valuable collaborative relationship with exercise physiologist Dr Ciara McCormack, and this year we began work on physical activity resources to help people benefit from moving more with PH. Work on these resources continues.

Our online peer support groups for people affected by PH have continued to grow and provide a vital source of connection for both patients and caregivers.

Our ongoing partnership with the financial hardship charity Turn2Us continues to give members access to valuable advice and resources around financial matters.

Our two websites have continued to develop with the addition of regular new content. And all of our publications and resources have continued to be made available to order for free from our website, with shipments made to all of the specialist centres too.

AWARENESS RAISING, MEMBER ENGAGEMENT, AND FUNDRAISING

A special project in mid-2023 saw us collaborate with a PHA UK member to create a meaningful piece of artwork designed to raise awareness and foster a sense of belonging in the PH community. The partnership resulted in artwork that was made available as a free screensaver download, and it was also provided as a pull-out poster within our member magazine.

In September 2023, we supported a group of PH consultants from specialist centres across the UK in their fundraising challenge to cycle from Sheffield to Dublin. We boosted the profile of their efforts via PR and our own communications channels, produced a short film to document the challenge, and provided promotional materials for them to raise awareness of PH whilst they cycled. Outcomes included thousands of pounds raised for the PHA UK, and a huge appreciation from the PH community for seeing their doctors quite literally go the extra mile.

In November 2023, our annual awareness campaign PH Day UK saw huge engagement. The theme was delayed diagnosis, and a suite of films we produced shared the stories of nine people who had experienced the consequences of delays. We produced awareness packs and GP engagement packs, which were requested by hundreds of members, and our social media activity reached thousands.

PH Day UK also served as an income driver, with money raised through our integrated 'Walk for Hope' initiative - devised to bring people together via fundraising on the day.

Linked to PH Day UK activity, our push to raise the profile of delayed diagnosis saw us participate in a valuable round table event in London, representing the patient voice alongside clinicians to explore potential solutions to expedite diagnoses.

November 2023 also saw us advocate for the PH community with an open response to the Government's autumn statement citing potential changes to the benefits system. We sent open letters to the Chancellor of the Exchequer, as well as the PHA UK head office's constituency MP, calling for a benefits system that supports rather than vilifies those with disabilities and chronic illness.

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 30 APRIL 2024**

In February 2024, we brought the patient voice to a global event by exhibiting at the Pulmonary Vascular Research Institute (PVRI) Congress in London. There, we advocated for patients being central to all research - ensuring this type of illness is studied as a lived experience. The event also raised the profile of the charity amongst the international PH community.

Early 2024 also saw us produce much-needed materials to help promote our charity and the support it provides. The printed leaflet and accompanying short film have been used extensively to help people access our support.

Throughout 2023/24, our new member engagement forums to encourage participation in our work have gone from strength to strength. Our 'Feedback Forum' and 'Research Forum' have provided a pool of engaged members from which to seek feedback on resources and initiatives, and to invite to participate in research projects. Response rates to all requests have been high, and ongoing recruitment into the groups continues to be successful.

Our efforts to engage with the PH community (and the general public) via our influential social media channels has continued to reap rewards. Our audience across all platforms has grown considerably, and they remain a vital source of communication with our members and stakeholders.

The channels are used successfully to seek input and engagement into our own projects and to support external initiatives of interest to our community - such as World PH Day, Organ Donation Week, and Carers Week.

RESEARCH

A major piece of research for us this year was our survey to understand the nutritional challenges faced by people with PH, to enable us to provide targeted support in this area.

The first of its kind globally, the survey gathered responses during the spring and summer of 2023 - attracting 600 completions. The following months were spent analysing the findings and launching our reports; and we acted quickly on the findings by producing advice materials that our community told us they needed. The findings of the survey continue to underpin our work around nutrition, to support people to live well with PH.

The latter part of 2023 saw the launch of the results of our major survey into people's lived experiences of pulmonary hypertension. Our report, 'Breathless, not voiceless: What it means to live with PH today' was shared widely and has been referenced all over the world.

In addition, abstracts of both this research and our survey around COVID-19 experiences were accepted by the European Respiratory Society and presented at their conference.

We have also supported specialist centre-based researchers in studies into genetic research and IV therapy compliance, and continued to collaborate with psychologists in the testing of a self-help programme for people with depression and PH. We have also written numerous letters of support for researchers hoping to access funding for clinical trials.

November 2023 saw us host the National PH Research Forum for the first time, after providing a small amount of financial support to it for many years. Stepping in to save the event after the original organisers pulled out, we were able to use our influence and expertise to host a hugely successful conference that brought researchers together from across the UK to share study findings and learn from each other's work.

We generated substantial event sponsorship, providing a valuable income stream, and we will continue to host the event each year.

In early 2024 we began work on an innovative research project, PH_HD, to look at the person - not just the PH. This involved the establishment of a steering group, and plans were put in place for the first stage of the research to begin in April 2024.

SUPPORT AND EDUCATION FOR MEDICAL PROFESSIONALS

We have supported specialist centres by producing bespoke combined therapy information materials for patients, and through continued regular provision of our publications to distribute during appointments.

We continue to be a source of information for healthcare professionals working within PH, particularly nursing staff, by fielding enquiries and signposting to our resources.

Early 2024 also saw us publish and provide stocks of a bespoke notebook, designed for practical use by PH healthcare professionals as well as providing regular reminders of our services through the placement of adverts throughout.

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 30 APRIL 2024**

The 'PH Academy', our online medical education programme to upskill healthcare professionals, has continued in development, with significant progress made. This is due for launch in Q1 of 2025.

We have continued to provide ongoing support and secretarial input for both the PH Professionals and PH Physicians groups - including hosting in-person and hybrid meetings, developing resources for them, and producing monthly e-newsletters. Plus, we have continued to help steer a Great Ormond Street Children's Hospital 'working group' to help explore issues affecting paediatrics in PH.

CHARITY DEVELOPMENT

Work began in this financial year on the development of a new customer relationship management (CRM) platform to enable us to manage and support our membership in the most effective way. This is a major project, that will revolutionise how the charity operates and ultimately benefit those we seek to support. Funding for the project was secured via our successful application for a government Business Productivity and Digitisation grant.

Charity operations have also been improved via the implementation of a new telephone system, which allows for effective home working and improved routing of enquiries. The online technology enables us to triage calls to prioritise support for patients and their loved ones.

2024 got off to a strong start when our work to secure a prestigious award win for our Chair boosted the reputation of the charity and gave members increased confidence in its leadership. Following our submissions, Iain Armstrong was announced as 'Cardiovascular Nurse of the Year' by the British Journal of Nursing Awards, and he was also awarded silver in the 'Nurse of the Year' category.

The Board of Trustees was strengthened this financial year with the appointment of Julie Royle, who has lived with PH and been involved in our charity for many years.

Sales from our online shop products have continued to provide a steady income stream and work has taken place to develop the range of merchandise to maximise this funding source.

Global demand has continued for licenses for the use of EmPHasis-10, the quality-of-life measure developed by the PHA UK, generating a significant amount of income for the charity. It has now been translated into 29 languages, plus regional dialects.

We have continued to outsource our communications and design provision, and Verso Investment continue to provide support to the PHA UK and maintain the investment portfolio.

If you have any questions about the contents of this overview, please email office@phauk.org

FINANCIAL REVIEW

Investment policy and objectives

The charity has invested in a portfolio of investments currently held in Aegon, managed by IEP Financial. The investments are valued at market value at the year end in the accounts.

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 30 APRIL 2024**

FINANCIAL REVIEW

Financial review and reserves policy

The financial position of the charity as at 30 April 2024 was showing:-

	£
Unrestricted funds	1,320,065
Restricted funds	394
Total funds	<u>1,320,459</u> =====

At 30 April 2024, Pulmonary Hypertension Association UK had free reserves of £395,745 and £900,000 of designated funds as follows:

- Up to £250,000 towards the cost of academic/clinical research.
- Up to £80,000 towards the funding of awareness activities including setting up an All Parliamentary Group.
- Up to £350,000 towards the production of educational literature and Online content including, completion of ImPAHct survey and production of newsletters with the results for medical professionals and members, Listening to me, Listening to you publication, Provision of educational resources for patients with learning disabilities, PH Medical Education Programme, Educational needs of patients and caregivers in relation to end of life care, practical aspects of daily living with PH, welfare benefit advice and the like.
- Up to £50,000 towards fundraising activities.
- Up to £65,000 as a contingency reserve.
- Up to £105,000 towards arranging patient & peer educational and support events that can be undertaken within the constraints arising from the pandemic.

Where funds set aside for research are subsequently spent the expenditure is inclusive of both the charity's own unrestricted funds and contributions from third party partners including industry.

The trustees aim to maintain free reserves in unrestricted funds at a level which equates to approximately 6 months of unrestricted charitable expenditure. The trustees consider that this level will provide sufficient funds to support the work of the charity for the short term should any of the charity income cease unexpectedly,

Going concern

There are no material uncertainties about the charity's ability to continue as a going concern.

Income from supporters via fundraising, legacies, regular giving (including our lottery), and one-off donations continues to reach us. We are currently developing a targeted three year fundraising strategy to ensure this continues.

Based on the preceding 12 months, we forecast an increase in sponsorship of our events, which will provide a significant boost to our income.

We continue to benefit from industry support, with transparent and ethical grants from pharmaceutical companies assisting us with mutual objectives, and there is no reason to see this changing. We are working to build relationships with new and emerging companies to secure future investment in this way.

Our investments continue to be well-managed, and forecasting from our investment advisors continues to be positive, and we have three years of reserves.

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 30 APRIL 2024**

FUTURE PLANS

It is envisaged that future developments would include: -

- The provision of funding directed towards wide-ranging research into all aspects of PH.
- The research and development of further educational literature relating to pulmonary hypertension for patients, carers, nurses, and others. We have and continue to fund research meeting and conferences for health care professionals working in the field of PH, these are both national and international in their makeup.
- The provision of funding to the specialist PH centres for research and nursing staff and other support staff.

Having evaluated outcomes from our activities over the preceding 12 months, we have targeted our future plans to ensure we are allocating resources in the best way.

The previous year saw extremely positive outputs from the healthcare professional meetings and conferences that we funded, and recognising this positive return on investment, we will continue to support these events.

Research we have funded over the previous year has led to tangible outcomes for people affected by PH and so we will continue to provide support in this way to research that aligns with our charitable objectives. We will also carry out our own research, building on previous findings to influence standards of care for patients and increase understanding of lived experiences.

Survey work amongst our members has identified multiple areas of unmet need, so we will be developing patient and carer resources on a range of topics including nutrition, mental health, and physical activity. This resource development work will also include collaborating with physicians to produce information materials for those with PH and congenital heart disease.

All of the resources highlighted above will also be utilised by medical staff as part of their interactions with patients.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

Pulmonary Hypertension Association UK is a private company limited by guarantee (registered in England & Wales), governed by its Memorandum and Articles of Association (company number 06268494) and registered with the charity commission (charity number 1120756).

Members of the company guarantee £1 in the event of the company being wound up. There are currently 5 members being the Charity Trustees

The Charitable Company's powers ("the powers") are:

In furtherance of the objects but not otherwise the Management Committee may exercise the following powers:

- (i) power to raise funds and to invite and receive contributions provided that in raising funds the Management Committee shall not undertake any substantial permanent trading activities and shall conform to any relevant requirements of the law;
- (ii) power to buy, take on lease or in exchange any property necessary for the achievement of the objects and to maintain and equip it for use;
- (iii) power subject to any consents required by law to sell, lease or dispose of all or any part of the property of the Charitable Company;
- (iv) power subject to any consents required by law to borrow money and to charge all or any part of the property of the Charitable Company with repayment of the money so borrowed;
- (v) power to employ such staff (who shall not be members of the Management Committee) as are necessary for the proper pursuit of the objects and to make all reasonable and necessary provision for the payment of pensions and superannuation for staff and their dependants;
- (vi) power to co-operate with other charities, voluntary bodies and statutory authorities operating in furtherance of the objects or of similar charitable purposes and to exchange information and advice with them;
- (vii) power to establish or support any charitable trusts, associations or institutions formed for all or any of the objects;
- (viii) power to appoint and constitute such advisory committees as the Management Committee may think fit;
- (ix) power to do all such other lawful things as are necessary for the achievement of the objects;
- (x) power to provide financial assistance towards research activities for members of the medical profession.

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 30 APRIL 2024**

STRUCTURE, GOVERNANCE AND MANAGEMENT

Recruitment and appointment of new trustees

Appointment of the management committee is governed by the charitable company's memorandum and articles.

The directors of the company are also charity trustees for the purposes of charity law and are known as members of the Management Committee. Under the requirements of the Memorandum and Articles of Association at each annual general meeting one third of the trustees are subject to retirement by rotation and may be re-elected.

All members of the Management committee give their time voluntarily and received no benefits from the charity. Any expenses reclaimed from the charity are set out in note 10 to the accounts.

Training of charity trustees is in accordance with advice published by the charity commission.

Decision making is carried out democratically during regular trustee meetings, held at least annually. Major decisions are documented in meeting minutes which are held by the secretary. Minutes are circulated to trustees before being signed off.

Organisational structure

Shaun Clayton (Operations and Finance Director) is delegated to deal with the day to day management of the charity after discussions with the trustees.

Related parties

Due to the nature of the charity's operations and the composition of the Board of Trustees being drawn from local and national public and private sector organisations, it is inevitable that transactions will take place with organisations in which a member of the board of trustees may have an interest. Any such transactions are conducted at arm's length and in accordance with the charity's financial regulations and normal procurement procedures.

On 31 July 2010 the net assets and operations of Pulmonary Hypertension Association (UK), a unincorporated registered charity (charity number 1082613) were transferred to the charity at net book value.

The trustees of Pulmonary Hypertension Association UK are also trustees of Pulmonary Hypertension Association (UK).

Donations totalling £178,107 were made to the charity by Pulmonary Hypertension Association (UK) (2023 - £187,836).

At 30th April 2024, £41,663 was due from Pulmonary Hypertension Association (UK) (2023 - £13,556).

Details of Trustee's interests are summarised below;

In order to provide clarity and to comply with advice from the Charity Commission on dealing with potential conflicts of interest the Pulmonary Hypertension Association UK wishes to make public a register of trustee's interest.

Mr Iain Armstrong, Chairman and Executive trustee is employed by Sheffield Teaching Hospitals NHS Trust.

Mr Iain Armstrong receives remuneration from Pulmonary Hypertension Association UK for consultancy. Pulmonary Hypertension UK pays Sheffield Teaching Hospitals NHS Trust for Mr Armstrong's services other than those as a trustee.

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees (who are also the directors of Pulmonary Hypertension Association UK for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 30 APRIL 2024**

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by order of the board of trustees on 28 January 2025 and signed on its behalf by:

Iain Armstrong

I J Armstrong - Trustee

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
PULMONARY HYPERTENSION ASSOCIATION UK**

Independent examiner's report to the trustees of Pulmonary Hypertension Association Uk ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 30 April 2024.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Patricia Richards

Patricia Richards BA ,FCA, DChA.
The Institute of Chartered Accountants in England and Wales

Wyatt Morris Golland Ltd
Park House
200 Drake Street
Rochdale
Lancashire
OL16 1PJ

28 January 2025

PULMONARY HYPERTENSION ASSOCIATION UK

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 30 APRIL 2024**

	Notes	Unrestricted funds £	Restricted funds £	2024 Total funds £	2023 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	438,746	8,500	447,246	363,802
Other trading activities	3	80,050	-	80,050	54,600
Investment income	4	1,637	-	1,637	1,430
Total		520,433	8,500	528,933	419,832
EXPENDITURE ON					
Raising funds	5	18,364	-	18,364	14,555
Charitable activities	6				
Charitable activities		551,448	9,400	560,848	541,739
Total		569,812	9,400	579,212	556,294
Net gains/(losses) on investments		109,738	-	109,738	(66,685)
NET INCOME/(EXPENDITURE)		60,359	(900)	59,459	(203,147)
Transfers between funds	18	(900)	900	-	-
Net movement in funds		59,459	-	59,459	(203,147)
RECONCILIATION OF FUNDS					
Total funds brought forward		1,260,606	394	1,261,000	1,464,147
TOTAL FUNDS CARRIED FORWARD		1,320,065	394	1,320,459	1,261,000

The notes form part of these financial statements

BALANCE SHEET
30 APRIL 2024

	Notes	Unrestricted funds £	Restricted funds £	2024 Total funds £	2023 Total funds £
FIXED ASSETS					
Tangible assets	13	24,320	-	24,320	21,725
Investments	14	1,114,213	-	1,114,213	1,014,159
		<u>1,138,533</u>	<u>-</u>	<u>1,138,533</u>	<u>1,035,884</u>
CURRENT ASSETS					
Stocks	15	12,571	-	12,571	4,393
Debtors	16	128,755	-	128,755	65,155
Cash at bank and in hand		117,092	394	117,486	235,065
		<u>258,418</u>	<u>394</u>	<u>258,812</u>	<u>304,613</u>
CREDITORS					
Amounts falling due within one year	17	(76,886)	-	(76,886)	(79,497)
NET CURRENT ASSETS		<u>181,532</u>	<u>394</u>	<u>181,926</u>	<u>225,116</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>1,320,065</u>	<u>394</u>	<u>1,320,459</u>	<u>1,261,000</u>
NET ASSETS		<u>1,320,065</u>	<u>394</u>	<u>1,320,459</u>	<u>1,261,000</u>
FUNDS	18				
Unrestricted funds				1,320,065	1,260,606
Restricted funds				394	394
TOTAL FUNDS				<u>1,320,459</u>	<u>1,261,000</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2024 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 28 January 2025 and were signed on its behalf by:

Iain Armstrong

I J Armstrong - Trustee

PULMONARY HYPERTENSION ASSOCIATION UK

**CASH FLOW STATEMENT
FOR THE YEAR ENDED 30 APRIL 2024**

	Notes	2024 £	2023 £
Cash flows from operating activities			
Cash generated from operations	1	<u>(115,290)</u>	<u>(57,815)</u>
Net cash used in operating activities		<u>(115,290)</u>	<u>(57,815)</u>
 Cash flows from investing activities			
Purchase of tangible fixed assets		(12,719)	(8,194)
Purchase of fixed asset investments		(78,976)	-
Sale of tangible fixed assets		-	366
Sale of fixed asset investments		87,769	8,265
Interest received		<u>1,637</u>	<u>1,301</u>
Net cash (used in)/provided by investing activities		<u>(2,289)</u>	<u>1,738</u>
 Change in cash and cash equivalents in the reporting period		<u>(117,579)</u>	<u>(56,077)</u>
Cash and cash equivalents at the beginning of the reporting period		<u>235,065</u>	<u>291,142</u>
 Cash and cash equivalents at the end of the reporting period		<u><u>117,486</u></u>	<u><u>235,065</u></u>

The notes form part of these financial statements

PULMONARY HYPERTENSION ASSOCIATION UK

**NOTES TO THE CASH FLOW STATEMENT
FOR THE YEAR ENDED 30 APRIL 2024**

1. RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2024	2023
	£	£
Net income/(expenditure) for the reporting period (as per the Statement of Financial Activities)	59,459	(203,147)
Adjustments for:		
Depreciation charges	9,754	9,148
(Gain)/losses on investments	(109,738)	66,685
Loss on disposal of fixed assets	369	1,704
Interest received	(1,637)	(1,301)
Investment income redistributed	892	-
(Increase)/decrease in stocks	(8,178)	2,895
(Increase)/decrease in debtors	(63,600)	64,637
(Decrease)/increase in creditors	(2,611)	1,564
Net cash used in operations	(115,290)	(57,815)

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.5.23	Cash flow	At 30.4.24
	£	£	£
Net cash			
Cash at bank and in hand	235,065	(117,579)	117,486
	235,065	(117,579)	117,486
Total	235,065	(117,579)	117,486

The notes form part of these financial statements

PULMONARY HYPERTENSION ASSOCIATION UK

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2024

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

Critical accounting judgements and key sources of estimation uncertainty

In the process of applying the entity's accounting policies management have not made any judgements that would have a significant effect on the amounts recognised in the financial statements. No estimations have been made that would have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Allocation and apportionment of costs

The costs are allocated between each relevant fund as directed by the trustees. Costs are apportioned to match the correct period to which they relate.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 15% on reducing balance
Office equipment	- 50% on cost and 25% on reducing balance

At each balance sheet date, the Charity reviews the carrying amounts of its property, plant and equipment to determine whether there is any indication that any items of property, plant and equipment have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss, if any. Where it is not possible to estimate the recoverable amount of the assets, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. Impairment loss is recognised as an expense immediately.

Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount and would have been determined (net of depreciation) had no impairment loss been recognised for the asset in prior years. A reversal of an impairment loss is recognised as income immediately.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

PULMONARY HYPERTENSION ASSOCIATION UK

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2024

1. ACCOUNTING POLICIES - continued

Fund accounting

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Financial instruments

Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Financial Instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Fixed Asset Investment

The charitable company holds an investment in a portfolio of shares managed by an independent Investment Broker. In accordance with FRS 102, these investments are recorded on the balance sheet at fair value and the net gains or losses are recorded in the Statement of Financial Activities, along with any investment income received.

2. DONATIONS AND LEGACIES

	2024	2023
	£	£
Donations	213,273	157,447
Legacies	11,037	10,500
Grants	36,000	-
Donations received from PHA (UK)	178,107	187,836
Other income	8,829	8,019
	<u>447,246</u>	<u>363,802</u>

Grants received, included in the above, are as follows:

	2024	2023
	£	£
Bayer	15,000	-
MSD	7,500	-
Janssen	7,000	-
Gossame	5,000	-
AOP	1,500	-
	<u>36,000</u>	<u>-</u>

PULMONARY HYPERTENSION ASSOCIATION UK

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 APRIL 2024**

3. OTHER TRADING ACTIVITIES

	2024	2023
	£	£
Emphasis 10 licence fees	25,350	54,600
PHA Exhibitions	54,700	-
	<u>80,050</u>	<u>54,600</u>

PHA UK has received money for the provision of Emphasis 10 licence fees from pharmaceutical companies to help with their research projects to better understand pulmonary hypertension. This research will advance education and awareness of the condition. This income has been classed as trading income but this ancillary trading contributes indirectly to the success and furtherance of the purposes of the charity.

During the year PHA UK has received sponsorship money to provide PHA exhibitions which provide support and provide information through the PHA support network.

4. INVESTMENT INCOME

	2024	2023
	£	£
Investment income	-	129
Deposit account interest	1,637	1,301
	<u>1,637</u>	<u>1,430</u>

5. RAISING FUNDS

Raising donations and legacies

	2024	2023
	£	£
Commissions and fundraising	7,887	8,378
Fundraising costs	10,477	6,177
	<u>18,364</u>	<u>14,555</u>

6. CHARITABLE ACTIVITIES COSTS

	Direct Costs (see note 7)	Support costs (see note 8)	Totals
	£	£	£
Charitable activities	336,466	224,382	560,848

PULMONARY HYPERTENSION ASSOCIATION UK

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 APRIL 2024**

7. DIRECT COSTS OF CHARITABLE ACTIVITIES

	2024	2023
	£	£
Printing, newsletters, merchandise, etc.	174,799	175,799
National awareness/fundraising (including DVD's and books)	30,190	17,212
Support meetings	6,991	28,550
Medical research	55,026	64,640
Support services	10,700	7,964
Consultants and professionals fees	10,413	21,396
Exhibitions and educational conferences	48,347	-
Bad debts	-	870
	<u>336,466</u>	<u>316,431</u>

8. SUPPORT COSTS

	Management	Finance	Governance	Totals
	£	£	costs £	£
Charitable activities	<u>195,729</u>	<u>10,129</u>	<u>18,524</u>	<u>224,382</u>

9. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2024	2023
	£	£
Auditors remuneration	-	6,100
Depreciation - owned assets	9,754	9,148
Deficit on disposal of fixed assets	369	1,704
Auditors remuneration non audit work	<u>6,817</u>	<u>6,652</u>

10. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 30th April 2024, nor for the year ended 30th April 2023.

Trustees Expenses:

	2024	2023
	£	£
Amounts paid to trustees	<u>54,374</u>	<u>57,854</u>

No grants were paid to any trustee during the year (2023 - £Nil).

No honorarium was paid to any trustee during the year (2023 - £Nil).

One trustee received £21,562 for consultancy fees in the year for services other than as a trustee, and £20,914 for secondment to the charity (2023 total - £49,487). These amounts are included in the totals above, and £3,416 is included in Other Creditors in respect of these fees (2023 - £528).

PULMONARY HYPERTENSION ASSOCIATION UK

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 APRIL 2024**

10. TRUSTEES' REMUNERATION AND BENEFITS - continued

Trustees' expenses

Other expenses includes travel, subsistence and administrative expenses, the number of trustees reimbursed were 2.

11. STAFF COSTS

	2024	2023
	£	£
Wages and salaries	68,814	61,018
Social security costs	982	1,065
Other pension costs	1,000	956
	<u>70,796</u>	<u>63,039</u>

The average monthly number of employees during the year was as follows:

	2024	2023
	3	2
Administration	<u>3</u>	<u>2</u>

No employees received emoluments in excess of £60,000.

The salaries of key personnel in the year were £41,929 (2023 - £40,371).

12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	363,802	-	363,802
Other trading activities	54,600	-	54,600
Investment income	1,430	-	1,430
Total	<u>419,832</u>	<u>-</u>	<u>419,832</u>
EXPENDITURE ON			
Raising funds	14,555	-	14,555
Charitable activities			
Charitable activities	502,238	39,501	541,739
Total	<u>516,793</u>	<u>39,501</u>	<u>556,294</u>
Net gains/(losses) on investments	(66,685)	-	(66,685)
NET INCOME/(EXPENDITURE)	(163,646)	(39,501)	(203,147)
RECONCILIATION OF FUNDS			
Total funds brought forward	1,424,252	39,895	1,464,147
TOTAL FUNDS CARRIED FORWARD	<u><u>1,260,606</u></u>	<u><u>394</u></u>	<u><u>1,261,000</u></u>

PULMONARY HYPERTENSION ASSOCIATION UK

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 APRIL 2024

13. TANGIBLE FIXED ASSETS

	Fixtures and fittings £	Office equipment £	Totals £
COST			
At 1 May 2023	13,905	46,911	60,816
Additions	245	12,474	12,719
Disposals	-	(1,552)	(1,552)
	<u>14,150</u>	<u>57,833</u>	<u>71,983</u>
DEPRECIATION			
At 1 May 2023	8,607	30,484	39,091
Charge for year	832	8,922	9,754
Eliminated on disposal	-	(1,182)	(1,182)
	<u>9,439</u>	<u>38,224</u>	<u>47,663</u>
NET BOOK VALUE			
At 30 April 2024	<u>4,711</u>	<u>19,609</u>	<u>24,320</u>
At 30 April 2023	<u>5,298</u>	<u>16,427</u>	<u>21,725</u>

14. FIXED ASSET INVESTMENTS

	Listed Investments 2024 £	Listed Investments 2023 £
Market value at 1st May 2023	1,014,159	1,089,107
Additions	78,976	-
Disposals	(87,769)	(8,263)
Unrealised gain/(loss)	109,866	(66,589)
Realised loss	(1,019)	(96)
	<u>1,114,213</u>	<u>1,014,159</u>
Market value at 30th April 2024	<u>1,114,213</u>	<u>1,014,159</u>
Historical cost at 1st May 2023	913,565	921,187
Addition	78,976	-
Disposals	(80,190)	(7,622)
	<u>912,351</u>	<u>913,565</u>
Historical cost at 30th April 2024	<u>912,351</u>	<u>913,565</u>

PULMONARY HYPERTENSION ASSOCIATION UK

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 APRIL 2024**

15. STOCKS

	2024	2023
	£	£
Stocks	12,571	4,393

16. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024	2023
	£	£
Trade debtors	23,869	13,518
Pulmonary Hypertension Association (UK)	41,663	13,556
Accrued income	832	2,051
Prepayments	62,391	36,030
	128,755	65,155

17. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024	2023
	£	£
Trade creditors	11,139	23,829
Other creditors	3,416	551
Accruals and deferred income	62,331	55,117
	76,886	79,497

18. MOVEMENT IN FUNDS

	At 1.5.23	Net movement in funds	Transfers between funds	At 30.4.24
	£	£	£	£
Unrestricted funds				
General fund	360,606	345,135	(285,676)	420,065
Medical Research	250,000	(66,204)	66,205	250,001
Development and Printing of Booklets and Online content	350,000	(84,267)	84,267	350,000
Awareness Activities	80,000	(36,511)	36,511	80,000
Fundraising Activities	50,000	(17,500)	17,500	50,000
Contingency Fund	65,000	-	-	65,000
Patient & Peer, Education & Support Events	105,000	(80,294)	80,293	104,999
	1,260,606	60,359	(900)	1,320,065
Restricted funds				
Covid19	394	-	-	394
AOP - Travel grant	-	(180)	180	-
Pulmonary Hypertension Centres meeting	-	(720)	720	-
	394	(900)	900	394
TOTAL FUNDS	1,261,000	59,459	-	1,320,459

PULMONARY HYPERTENSION ASSOCIATION UK

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 APRIL 2024**

18. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	520,433	(285,036)	109,738	345,135
Medical Research	-	(66,204)	-	(66,204)
Development and Printing of Booklets and Online content	-	(84,267)	-	(84,267)
Awareness Activities	-	(36,511)	-	(36,511)
Fundraising Activities	-	(17,500)	-	(17,500)
Patient & Peer, Education & Support Events	-	(80,294)	-	(80,294)
	<u>520,433</u>	<u>(569,812)</u>	<u>109,738</u>	<u>60,359</u>
Restricted funds				
AOP - Travel grant	1,500	(1,680)	-	(180)
Pulmonary Hypertension Centres meeting	7,000	(7,720)	-	(720)
	<u>8,500</u>	<u>(9,400)</u>	<u>-</u>	<u>(900)</u>
TOTAL FUNDS	<u>528,933</u>	<u>(579,212)</u>	<u>109,738</u>	<u>59,459</u>

Comparatives for movement in funds

	At 1.5.22 £	Net movement in funds £	Transfers between funds £	At 30.4.23 £
Unrestricted funds				
General fund	524,251	15,444	(179,089)	360,606
Medical Research	250,000	(101,750)	101,750	250,000
Development and Printing of Booklets and Online content	350,000	(14,430)	14,430	350,000
Awareness Activities	80,000	(15,808)	15,808	80,000
Fundraising Activities	50,001	(17,246)	17,245	50,000
Contingency Fund	65,000	-	-	65,000
Patient & Peer, Education & Support Events	105,000	(29,856)	29,856	105,000
	<u>1,424,252</u>	<u>(163,646)</u>	<u>-</u>	<u>1,260,606</u>
Restricted funds				
Covid-19 Impact	39,895	(39,501)	-	394
TOTAL FUNDS	<u>1,464,147</u>	<u>(203,147)</u>	<u>-</u>	<u>1,261,000</u>

PULMONARY HYPERTENSION ASSOCIATION UK

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 APRIL 2024**

18. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	419,832	(337,703)	(66,685)	15,444
Medical Research	-	(101,750)	-	(101,750)
Development and Printing of Booklets and Online content	-	(14,430)	-	(14,430)
Awareness Activities	-	(15,808)	-	(15,808)
Fundraising Activities	-	(17,246)	-	(17,246)
Patient & Peer, Education & Support Events	-	(29,856)	-	(29,856)
	419,832	(516,793)	(66,685)	(163,646)
Restricted funds				
Covid-19 Impact	-	(39,501)	-	(39,501)
TOTAL FUNDS	419,832	(556,294)	(66,685)	(203,147)

Details of designated funds

At 30 April 2024, Pulmonary Hypertension Association UK had £900,000 of unrestricted funds currently designated as follows:

- Up to £250,000 towards the cost of academic/clinical research.
- Up to £80,000 towards the funding of awareness activities including setting up an All Parliamentary Group.
- Up to £350,000 towards the production of educational literature and Online content including, completion of ImPAHct survey and production of newsletters with the results for medical professionals and members, Listening to me, Listening to you publication, Provision of educational resources for patients with learning disabilities, PH Medical Education Programme, Educational needs of patients and caregivers in relation to end of life care, practical aspects of daily living with PH, welfare benefit advice and the like.
- Up to £50,000 towards fundraising activities.
- Up to £65,000 as a contingency reserve.
- Up to £105,000 towards arranging patient & peer educational and support events that can be undertaken within the constraints arising from the pandemic.

Where funds set aside for research are subsequently spent the expenditure is inclusive of both the charity's own unrestricted funds and contributions from third party partners including industry

Transfer between funds

Where expenditure on a restricted fund project exceeds the level of restricted funds a transfer is made from unrestricted funds to cover the shortfall

Where previously designated funds have been utilised and the trustees consider the designation appropriate for a future period there is a transfer from unrestricted funds to make up the required designated balance.

PULMONARY HYPERTENSION ASSOCIATION UK

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 APRIL 2024**

19. OTHER FINANCIAL COMMITMENTS

Commitments under operating lease agreements.

At 30 April 2024 the charity had total commitments under non-cancellable operating leases as follows;

	2024		2023	
Expiry date:	Land & Building £	Other £	Land & Building £	Other £
Less than 1 year	-	-	-	7,168
Within 1 to 5 years	51,711	-	90,494	-
	<u>51,711</u>	<u>-</u>	<u>90,494</u>	<u>7,168</u>

20. RELATED PARTY DISCLOSURES

Due to the nature of the charity's operations and the composition of the Board of Trustees being drawn from local and national public and private sector organisations, it is inevitable that transactions will take place with organisations in which a member of the board of trustees may have an interest. Any such transactions are conducted at arm's length and in accordance with the charity's financial regulations and normal procurement procedures.

Details of trustee's interests are contained within the trustees report , and note 8.

On 31 July 2010 the net assets and operations of Pulmonary Hypertension Association (UK), an unincorporated charity (charity number 1082613) were transferred to the charity at net book value.

The trustees of Pulmonary Hypertension Association UK are also trustees of Pulmonary Hypertension Association (UK).

Donations totalling £178,107 were made to the charity by Pulmonary Hypertension Association (UK) (2023 - £187,836).

At 30 April 2024, £41,663 was due from Pulmonary Hypertension Association (UK) (2023 - £13,556).

21. RESTRICTED FUNDS

Covid-19 Impact

A grant was received to support PHA's research project on the impact of the Covid-19 pandemic on people affected by Pulmonary Hypertension.

AOP - Travel grant

A grant was received to support I Armstrong travelling to the ERS conference.

Pulmonary Hypertension Centres meeting

JC General Services (Janssen) paid a grant to the charity to support the Pulmonary Hypertension Centres best practice shared care meeting bringing together the perspectives of all the PH centres across the UK. The grant went towards venue hire, catering costs and travel.



Issuer wyatt morris golland ltd

Document generated Tue, 28th Jan 2025 15:43:01 GMT

Document fingerprint 7720c6fc20c860d85a6e844c11d951b3

Parties involved with this document

Document processed	Party + Fingerprint
Wed, 29th Jan 2025 11:06:30 GMT	Iain Armstrong - Signer (839b077a78e2a18fc4755b969c0db917)
Wed, 29th Jan 2025 11:29:44 GMT	patricia richards - Signer (983add9f80ff39ccd54f6e17c88bb614)

Audit history log

Date	Action
Wed, 29th Jan 2025 11:29:45 GMT	patricia richards viewed the envelope (81.149.113.49)
Wed, 29th Jan 2025 11:29:44 GMT	This envelope has been signed by all parties (81.149.113.49)
Wed, 29th Jan 2025 11:29:44 GMT	patricia richards signed the envelope (81.149.113.49)
Wed, 29th Jan 2025 11:28:04 GMT	patricia richards viewed the envelope (81.149.113.49)
Wed, 29th Jan 2025 11:27:55 GMT	patricia richards opened the document email. (81.149.113.49)
Wed, 29th Jan 2025 11:27:53 GMT	patricia richards opened the document email. (81.149.113.49)
Wed, 29th Jan 2025 11:06:31 GMT	Iain Armstrong viewed the envelope (84.18.229.123)
Wed, 29th Jan 2025 11:06:31 GMT	Document emailed to patriciarichards@e-wmg.co.uk (18.168.254.5)
Wed, 29th Jan 2025 11:06:31 GMT	Sent the envelope to patricia richards (patriciarichards@e-wmg.co.uk) for signing (84.18.229.123)
Wed, 29th Jan 2025 11:06:30 GMT	Iain Armstrong signed the envelope (84.18.229.123)
Wed, 29th Jan 2025 11:05:40 GMT	Iain Armstrong viewed the envelope (84.18.229.123)
Wed, 29th Jan 2025 10:56:44 GMT	Iain Armstrong opened the document email. (104.28.86.106)
Tue, 28th Jan 2025 16:24:08 GMT	Iain Armstrong opened the document email. (104.28.86.106)
Tue, 28th Jan 2025 15:45:17 GMT	Document emailed to iain@phauk.org (18.134.5.107)
Tue, 28th Jan 2025 15:45:17 GMT	Sent the envelope to Iain Armstrong (iain@phauk.org) for signing (81.149.113.49)
Tue, 28th Jan 2025 15:43:03 GMT	Document generated with fingerprint 6e7e45e0a68d02406ffe708ebac481b1 (81.149.113.49)
Tue, 28th Jan 2025 15:43:02 GMT	Document generated with fingerprint 7720c6fc20c860d85a6e844c11d951b3 (81.149.113.49)

Tue, 28th Jan 2025 15:43:02 GMT

Document generated with fingerprint bab076f39f6c815a9c534a158507fe9e
(81.149.113.49)

Tue, 28th Jan 2025 15:43:01 GMT

Envelope generated by patricia richards (81.149.113.49)